SAB Biotherapeutics (NASDAQ:SABS) Stock Price Breaks Above 50-Day Moving Average – Should You Sell?

by · The Markets Daily

SAB Biotherapeutics, Inc. (NASDAQ:SABS – Get Free Report) shares passed above its 50 day moving average during trading on Friday. The stock has a 50 day moving average of $3.26 and traded as high as $3.37. SAB Biotherapeutics shares last traded at $3.35, with a volume of 741,051 shares trading hands.

Wall Street Analyst Weigh In

SABS has been the subject of several analyst reports. Wall Street Zen upgraded shares of SAB Biotherapeutics from a “strong sell” rating to a “sell” rating in a research report on Monday, August 10th. Weiss Ratings upgraded shares of SAB Biotherapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday, September 17th. Nine equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $12.00.

View Our Latest Report on SABS

SAB Biotherapeutics Price Performance

The company has a fifty day moving average of $3.26 and a 200-day moving average of $3.68. The company has a current ratio of 9.22, a quick ratio of 9.22 and a debt-to-equity ratio of 0.01. The stock has a market cap of $304.82 million, a PE ratio of -2.58 and a beta of 0.58.

SAB Biotherapeutics (NASDAQ:SABS – Get Free Report) last announced its quarterly earnings data on Thursday, August 6th. The company reported ($0.28) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.28). Sell-side analysts expect that SAB Biotherapeutics, Inc. will post -1.17 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of SABS. PNC Financial Services Group Inc. acquired a new position in shares of SAB Biotherapeutics in the first quarter valued at about $29,000. IFP Advisors Inc bought a new stake in shares of SAB Biotherapeutics in the 2nd quarter worth approximately $151,000. Bank of America Corp DE grew its holdings in shares of SAB Biotherapeutics by 424.8% during the first quarter. Bank of America Corp DE now owns 55,697 shares of the company’s stock worth $213,000 after purchasing an additional 45,084 shares in the last quarter. Kestra Advisory Services LLC raised its stake in shares of SAB Biotherapeutics by 434.6% during the first quarter. Kestra Advisory Services LLC now owns 61,741 shares of the company’s stock valued at $236,000 after acquiring an additional 50,191 shares during the last quarter. Finally, Bank of New York Mellon Corp purchased a new stake in SAB Biotherapeutics during the 2nd quarter valued at about $421,000. Institutional investors own 7.82% of the company’s stock.

SAB Biotherapeutics Company Profile

(Get Free Report)

SAB Biotherapeutics, Inc is a biotechnology company focused on developing fully human polyclonal antibody medicines for infectious diseases, immune disorders and other conditions where targeted immune responses may provide therapeutic benefits. The company is based in Sioux Falls, South Dakota.

SAB Biotherapeutics uses its DiversitAb platform, which involves genetically engineered cattle capable of producing antibodies with human immune-system characteristics. Antibodies are collected from the animals’ plasma and processed for potential use as treatments, allowing the company to pursue antibody products without relying solely on conventional human donor sources.

The company has developed a pipeline that has included SAB-185, an investigational antibody therapy directed at SARS-CoV-2, as well as programs targeting influenza and autoimmune or immune-mediated diseases.

Recommended Stories